Exelixis, Inc.
EXEL Biological Products, (No Diagnostic Substances) · Nasdaq
Market statistics
Measured from daily returns over the past year. That is not the same estimator as the beta quoted on most finance sites, which is usually five years of monthly returns, and in a market where single stocks move on their own news the daily figure comes out materially lower. Over this window the average large-cap correlation to the index is far below its long-run level: a low number here is a statement about the last twelve months, not a claim that the security is uncorrelated with the market in general.
As filed with the SEC twelve months to 2025-12-31 · balance sheet 2026-03-31
Short selling — three different measurements
These measure different things and are routinely confused. Shares short is an outstanding position, reported twice monthly (settlement 2026-08-14). Short share of volume counts sell-side transactions flagged short each day, most of which is market-maker hedging closed the same session — the market-wide median is around half. Fail balances are shares that did not settle on time; the SEC states these are cumulative balances whose age cannot be determined, and they are not evidence of naked short selling.
Ownership
Largest reported holdersamong the managers stored here
| Manager | Reported value | Shares |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $588.8M | 13,726,993 |
| AQR CAPITAL MANAGEMENT LLC | $561.7M | 13,095,741 |
| FULLER & THALER ASSET MANAGEMENT, INC. | $366.4M | 8,542,236 |
| ASSETMARK, INC | $145.4M | 3,388,920 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $133.1M | 3,102,634 |
| Caisse de depot et placement du Quebec | $109.1M | 2,542,819 |
| JUPITER ASSET MANAGEMENT LTD | $41.5M | 967,409 |
| Retirement Systems of Alabama | $37.3M | 869,072 |
Schedule 13D activist stakesfilers declaring intent to influence
| Filer | % of class | Filed | Form |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 5.6% | 2026-08-14 | SCHEDULE 13D/A |
On the public record
Insider trading 0 open-market buys, 1 sells by 1 insiders · latest 2026-08-10 Congress trading 3 disclosed trades by 1 members · latest 2019-06-04 Filings on EDGAR CIK 939767
Moves most like
| Ticker | 1-year correlation | Volatility vs EXEL |
|---|---|---|
| INCY Incyte Corporation | 0.484 | 0.90× |
| NBIX Neurocrine Biosciences, Inc. | 0.458 | 0.89× |
| XBI State Street SPDR S&P Biotech ETF | 0.444 | 0.75× |
| MIRM Mirum Pharmaceuticals, Inc. | 0.415 | 1.23× |
| ACAD ACADIA Pharmaceuticals Inc. | 0.384 | 1.02× |
| AMGN Amgen Inc. | 0.380 | 0.80× |
| RPRX Royalty Pharma plc - Class A Ordinary Shares | 0.376 | 0.64× |
| GMAB Genmab A/S | 0.370 | 0.91× |
What is on this page
Everything this site holds about one security, from sources that are all public record. The figures come from different places and mean different things, so each block says where it came from.
- Filed by the company — the financial statements, taken from the SEC's XBRL data sets. As filed, unaudited by us, and twelve-month figures unless stated.
- Filed by someone else about the company — institutional positions on Form 13F, activist stakes on Schedule 13D, insider transactions on Form 4, congressional trades under the STOCK Act. All lag by design; 13F by up to 45 days.
- Reported by the market's plumbing — short interest and short volume from FINRA, settlement fails from the SEC.
- Computed here — volatility, beta, correlations and rate sensitivity, measured from daily returns. These are derived statistics; no price or return series is published anywhere on this site.
What is deliberately absent
No price, no chart, no market capitalisation, no valuation ratio. The daily price history behind the statistics above is licensed from a commercial vendor and cannot be republished — and publishing a market cap alongside a share count would hand the price straight back. Every number here is either a public filing or a statistic from which the underlying series cannot be reconstructed.
Coverage
US securities trading at least $1 million a day with three years of history. Sections appear only where there is something to show: a fund has no income statement, most companies have no activist stake, and only a few dozen listed companies hold material federal contracts.